These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11399864)

  • 21. Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics.
    Walker AL; Lancaster CS; Finkelstein D; Ware RE; Sparreboom A
    Am J Physiol Cell Physiol; 2013 Dec; 305(12):C1223-9. PubMed ID: 23986199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of hydroxyurea in children with sickle cell disease: what comes next?
    Ohene-Frempong K; Smith-Whitley K
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy.
    Saleh AW; Hillen HF; Duits AJ
    Acta Haematol; 1999; 102(1):31-7. PubMed ID: 10473885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale, Development, and Validation of HdxSim, a Clinical Decision Support Tool for Model-Informed Precision Dosing of Hydroxyurea for Children with Sickle Cell Anemia.
    Power-Hays A; Dong M; Punt N; Mizuno T; Smart LR; Vinks AA; Ware RE
    Clin Pharmacol Ther; 2024 Sep; 116(3):670-677. PubMed ID: 38018175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
    Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea.
    Ballas SK; Marcolina MJ; Dover GJ; Barton FB
    Br J Haematol; 1999 May; 105(2):491-6. PubMed ID: 10233426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of hydroxyurea on hemoglobin S].
    Torres AF; Eberle SE; Sciuccati G; Bonduel M
    Medicina (B Aires); 2003; 63(2):140-2. PubMed ID: 12793083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
    Sharef SW; Al-Hajri M; Beshlawi I; Al-Shahrabally A; Elshinawy M; Zachariah M; Mevada ST; Bashir W; Rawas A; Taqi A; Al-Lamki Z; Wali Y
    Eur J Haematol; 2013 Jun; 90(6):519-24. PubMed ID: 23489171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced plasma angiotensin II levels are reversed by hydroxyurea treatment in mice with sickle cell disease.
    dos Santos AF; Almeida CB; Brugnerotto AF; Roversi FM; Pallis FR; Franco-Penteado CF; Lanaro C; Albuquerque DM; Leonardo FC; Costa FF; Conran N
    Life Sci; 2014 Nov; 117(1):7-12. PubMed ID: 25219880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydroxyurea in the treatment of sickle-cell anemia.
    Howard LW; Kennedy LD
    Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between oxidative stress, glutathione S-transferase polymorphisms and hydroxyurea treatment in sickle cell anemia.
    Silva DG; Belini Junior E; Torres Lde S; Ricci Júnior O; Lobo Cde C; Bonini-Domingos CR; de Almeida EA
    Blood Cells Mol Dis; 2011 Jun; 47(1):23-8. PubMed ID: 21489839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS).
    Ware RE; Marahatta A; Ware JL; McElhinney K; Dong M; Vinks AA
    J Pediatr; 2020 Jul; 222():236-239. PubMed ID: 32171562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.
    Keikhaei B; Yousefi H; Bahadoram M
    Glob J Health Sci; 2015 Aug; 8(3):252-6. PubMed ID: 26493428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
    Sumoza A; de Bisotti R; Sumoza D; Fairbanks V
    Am J Hematol; 2002 Nov; 71(3):161-5. PubMed ID: 12410569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytokines and soluble adhesion molecules in sickle cell anemia patients during hydroxyurea therapy.
    Saleh AW; Duits AJ; Gerbers A; de Vries C; Hillen HF
    Acta Haematol; 1998; 100(1):26-31. PubMed ID: 9691143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma levels of TNF-alpha in sickle cell patients receiving hydroxyurea.
    Tavakkoli F; Nahavandi M; Wyche MQ; Perlin E
    Hematology; 2004 Feb; 9(1):61-4. PubMed ID: 14965870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxyurea in children: present and future.
    Vichinsky EP
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):22-9. PubMed ID: 9317198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
    Ballas SK; McCarthy WF; Guo N; Brugnara C; Kling G; Bauserman RL; Waclawiw MA
    Hemoglobin; 2010; 34(5):424-9. PubMed ID: 20854115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea.
    Friedrisch JR; Prá D; Maluf SW; Bittar CM; Mergener M; Pollo T; Kayser M; da Silva MA; Henriques JA; da Rocha Silla LM
    Mutat Res; 2008 Jan; 649(1-2):213-20. PubMed ID: 17988936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients.
    Al-Nood HA; Al-Khawlani MM; Al-Akwa A
    Hemoglobin; 2011; 35(1):13-21. PubMed ID: 21250877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.